INT73091

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.44
First Reported 1997
Last Reported 2011
Negated 0
Speculated 2
Reported most in Body
Documents 21
Total Number 23
Disease Relevance 6.64
Pain Relevance 0.93

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (TNFRSF8) plasma membrane (TNFRSF8) cytoplasm (TNFRSF8)
Anatomy Link Frequency
upper 2
HeLa 1
lymphocyte 1
appendix 1
TNFRSF8 (Homo sapiens)
Pain Link Frequency Relevance Heat
member 8 35 98.12 Very High Very High Very High
Inflammation 167 91.28 High High
abdominal pain 6 88.56 High High
Pain 3 82.16 Quite High
cytokine 87 80.68 Quite High
vincristine 3 75.60 Quite High
Inflammatory response 18 70.84 Quite High
rheumatoid arthritis 22 64.92 Quite High
agonist 17 24.40 Low Low
Spinal cord 1 10.24 Low Low
Disease Link Frequency Relevance Heat
Cancer 99 99.46 Very High Very High Very High
Epstein-barr Virus 77 99.46 Very High Very High Very High
Hemangiosarcoma 4 98.58 Very High Very High Very High
Stress 58 97.88 Very High Very High Very High
Apoptosis 74 97.08 Very High Very High Very High
Necrosis 38 96.64 Very High Very High Very High
Disease 53 95.86 Very High Very High Very High
Anaplastic Large Cell Lymphoma 20 92.12 High High
INFLAMMATION 185 91.28 High High
Lymphatic System Cancer 270 90.72 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Subsequent analysis of CD30 cell surface expression by flow cytometry and fluorescence microscopy revealed that a brief treatment of CD30+ cells with wild-type Trx1 led to the complete loss of CD30 recognition by the Ki-1 antibody (Figure 5A, upper panel and Figure 5B, second column).
CD30 Binding (recognition) of in upper
1) Confidence 0.44 Published 2007 Journal EMBO J Section Body Doc Link PMC1914094 Disease Relevance 0.13 Pain Relevance 0
Conversely, ectopic overexpression of several related TNFR superfamily members in HeLa cells did not lead to their interaction with Trx1, yet CD30 strongly interacted on the same cells under the same conditions.
CD30 Binding (interacted) of in HeLa
2) Confidence 0.44 Published 2007 Journal EMBO J Section Body Doc Link PMC1914094 Disease Relevance 0.09 Pain Relevance 0
Trx1-mediated disulfide exchange interferes with CD30 receptor–ligand interactions
CD30 Binding (interactions) of
3) Confidence 0.44 Published 2007 Journal EMBO J Section Body Doc Link PMC1914094 Disease Relevance 0.12 Pain Relevance 0
Additional immunoblotting experiments demonstrated that low nanomolar concentrations of Trx1(CSAAA) are sufficient to detect the interaction with CD30 (Figure 3B) and also confirmed that trapping of CD30 depends on the N-terminal cysteine of the CXXC motif (Figure 3C, lanes 1–8).
CD30 Binding (interaction) of
4) Confidence 0.44 Published 2007 Journal EMBO J Section Body Doc Link PMC1914094 Disease Relevance 0 Pain Relevance 0
The observation that antibody binding to CD30 is influenced by Trx1 suggested a redox-dependent conformational change within the CD30 ectodomain.
CD30 Binding (binding) of
5) Confidence 0.44 Published 2007 Journal EMBO J Section Body Doc Link PMC1914094 Disease Relevance 0.13 Pain Relevance 0
Application of the Grx1 trapping mutant under the same conditions did not lead to its conjugation to CD30 (Figure 3C, lanes 9 and 10).
CD30 Binding (conjugation) of
6) Confidence 0.44 Published 2007 Journal EMBO J Section Body Doc Link PMC1914094 Disease Relevance 0 Pain Relevance 0
A group of 15 patients with refractory Hodgkin's disease were treated in a phase I/II trial with the natural-killer (NK)-cell-activating bispecific monoclonal antibody HRS-3/A9, which is directed against the Fc gamma receptor III (CD16 antigen) and the Hodgkin's associated CD30 antigen.
CD30 Binding (associated) of associated with disease
7) Confidence 0.36 Published 1997 Journal Cancer Immunol. Immunother. Section Abstract Doc Link 9435869 Disease Relevance 0.41 Pain Relevance 0.08
In vitro studies focusing on CD30+ lymphoid malignancies showed that triggering of CD30 signaling can induce either proliferation, activation, growth arrest or apoptosis, depending on cell type and stimulatory conditions (Schneider and Hubinger, 2002).
CD30 Binding (triggering) of associated with apoptosis
8) Confidence 0.34 Published 2007 Journal EMBO J Section Body Doc Link PMC1914094 Disease Relevance 0.25 Pain Relevance 0.03
CD30/TNFRSF8 is the principal Trx1 sensitive receptor on various lymphoid cell lines
CD30 Binding (/) of
9) Confidence 0.34 Published 2007 Journal EMBO J Section Body Doc Link PMC1914094 Disease Relevance 0.24 Pain Relevance 0
The interaction between Trx1 and CD30 might represent a regulatory link between oxidative stress and lymphocyte function.
CD30 Spec (might) Binding (interaction) of in lymphocyte associated with stress
10) Confidence 0.34 Published 2007 Journal EMBO J Section Body Doc Link PMC1914094 Disease Relevance 0.93 Pain Relevance 0.18
To validate the direct covalent interaction between Trx1(CSAAA) and CD30, an aliquot of trapped complexes from the same experiment was separated under non-reducing and reducing conditions and subjected to immunoblotting analysis with anti-Trx1 (Figure 3A, middle panel) and anti-CD30 antibodies (Figure 3A, right panel), respectively.
CD30 Binding (interaction) of
11) Confidence 0.34 Published 2007 Journal EMBO J Section Body Doc Link PMC1914094 Disease Relevance 0.11 Pain Relevance 0
To test whether Trx1-mediated reduction of CD30 influences binding of CD30 to its ligand (CD30L), we analyzed the interaction between CD30 and recombinant soluble CD30L (sCD30L) on the cell surface by flow cytometry.
CD30 Binding (binding) of
12) Confidence 0.34 Published 2007 Journal EMBO J Section Body Doc Link PMC1914094 Disease Relevance 0.16 Pain Relevance 0
CD30/TNFRSF8 is the principal Trx1 sensitive receptor on various lymphoid cell lines
TNFRSF8 Binding (/) of
13) Confidence 0.34 Published 2007 Journal EMBO J Section Body Doc Link PMC1914094 Disease Relevance 0.24 Pain Relevance 0
To test whether Trx1-mediated reduction of CD30 influences binding of CD30 to its ligand (CD30L), we analyzed the interaction between CD30 and recombinant soluble CD30L (sCD30L) on the cell surface by flow cytometry.
CD30 Spec (analyzed) Binding (interaction) of
14) Confidence 0.34 Published 2007 Journal EMBO J Section Body Doc Link PMC1914094 Disease Relevance 0.17 Pain Relevance 0
Loss of CD30 antibody recognition typically occurred within minutes (Figure 5D, upper panel).
CD30 Binding (recognition) of in upper
15) Confidence 0.33 Published 2007 Journal EMBO J Section Body Doc Link PMC1914094 Disease Relevance 0 Pain Relevance 0
We demonstrate that the redox interaction is highly specific for both Trx1 and CD30 and that the redox state of CD30 determines its ability to engage the cognate ligand and transduce signals.
CD30 Binding (interaction) of
16) Confidence 0.33 Published 2007 Journal EMBO J Section Abstract Doc Link PMC1914094 Disease Relevance 0.19 Pain Relevance 0.17
In the reduced state, CD30 lost its ability to interact with its cognate ligand CD30L or agonistic antibodies.
CD30 Binding (interact) of
17) Confidence 0.33 Published 2007 Journal EMBO J Section Body Doc Link PMC1914094 Disease Relevance 0.20 Pain Relevance 0.03
We demonstrate that the redox interaction is highly specific for both Trx1 and CD30 and that the redox state of CD30 determines its ability to engage the cognate ligand and transduce signals.
CD30 Binding (engage) of
18) Confidence 0.33 Published 2007 Journal EMBO J Section Abstract Doc Link PMC1914094 Disease Relevance 0.19 Pain Relevance 0.17
This case is reported to illustrate the importance of considering the diagnosis of epithelioid angiosarcoma when encountering an "epithelioid" neoplasm particularly with unusual immunoreactivity for CK7 and CD30.
CD30 Binding (immunoreactivity) of associated with cancer and hemangiosarcoma
19) Confidence 0.28 Published 2010 Journal Diagn. Cytopathol. Section Abstract Doc Link 19813270 Disease Relevance 0.89 Pain Relevance 0.06
Extracellular thioredoxin has also been shown to regulate receptor-ligand signaling interactions, specifically the binding of CD30 to its cognate ligand [12].
CD30 Binding (binding) of
20) Confidence 0.13 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2780735 Disease Relevance 0.36 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox